Recent advances reveal that K63-linked ubiquitination, SUMOyation and perhaps tyrosine phosphorylation can contribute to Akt signaling activation in a PI3K-independent fashion, indicating that these modifications may be alternative mechanisms accounting for aberrant Akt hyperactivation in human cancers. The gene discussed is AKT1; the disease is cancer.